research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
German chemists Walter Noddack, Otto Berg, and Ida Tacke reported the discovery of element 75 and element 43 in 1925, and named element 43 masurium (after Masuria in eastern Prussia, now in Poland, the region where Walter Noddack's family originated). This name caused significant resentment in the scientific community, because it was interpreted as referring to a series of victories of the German army over the Russian army in the Masuria region during World War I; as the Noddacks remained in their academic positions while the Nazis were in power, suspicions and hostility against their claim for discovering element 43 continued. The group bombarded columbite with a beam of electrons and deduced element 43 was present by examining X-ray emission spectrograms. The wavelength of the X-rays produced is related to the atomic number by a formula derived by Henry Moseley in 1913. The team claimed to detect a faint X-ray signal at a wavelength produced by element 43. Later experimenters could not replicate the discovery, and it was dismissed as an error. Still, in 1933, a series of articles on the discovery of elements quoted the name masurium for element 43. Some more recent attempts have been made to rehabilitate the Noddacks' claims, but they are disproved by Paul Kuroda's study on the amount of technetium that could have been present in the ores they studied: it could not have exceeded 3 × 10−11 μg/kg of ore, and thus would have been undetectable by the Noddacks' methods.
The inaugural Foundation scholar was nobel laureate Linus Pauling and the Foundation has brought many other eminent research chemists to Australia. The Foundation has thus functioned to increase Australian awareness of state of the art international research, increased international recognition of Australian research, and allowed graduate students to interact with leading chemists based in institutions far from Australia. Many of the students have gone on to post-graduate or post-doctoral positions with a Foundation scholar. Freeman also provided advice to the Australian Government on the problem of access to "big science" facilities. This included making major contributions to the report Small Country - Big Science in his work for the Australian Science and Technology Council. The report emphasised the need for Australian researchers to have access to facilities such as synchrotron X-ray and high intensity neutron sources, and led directly to the formation of the Australian Synchrotron Research Programme (ASRP) to fund access to such facilities. Freeman served as a board member of the ASRP until its functions were subsumed under the newly commissioned Australian Synchrotron in 2008. The Australian expertise developed as a consequence of ASRP-supported research led to the Australian Synchrotron being built a decade sooner than would have otherwise been the case. Freeman retired from his Chair in 1997, and was succeeded by Len Lindoy FAA.
=== Gómez, France 1998 and the end of the cycle (1995–1999) === Hernán Darío Gómez, known as El Bolillo, replaced Maturana in 1995. Colombia lost 2–0 to the hosts Uruguay in the semi-finals of the 1995 Copa América before beating the United States 4–1 in Maldonado to take third place, Wilmer Cabrera, Valderrama, Asprilla and Rincón all scoring. Two years later they were eliminated 2–1 by the hosts Bolivia in the quarter-finals of the 1997 Copa América. Colombia reached the 1998 FIFA World Cup by finishing third in the first CONMEBOL qualifying tournament contested as a single home-and-away league, taking 28 points from sixteen matches — two behind Argentina and one behind Paraguay — with Asprilla their leading scorer on seven goals, including a hat-trick in a 4–1 win over Chile in Barranquilla. Drawn in Group G with Tunisia, England and Romania, they lost 1–0 to Romania, beat Tunisia 1–0, and were eliminated on 26 June by England at the Stade Bollaert-Delelis in Lens. Darren Anderton volleyed England ahead in the 20th minute and David Beckham curled in a free kick from some 30 yards nine minutes later for his first international goal, Faryd Mondragón keeping the margin to 2–0 thereafter.
Sources: en.wikipedia.org
== Ureas == Urea (O=C(NH2)2) is more basic at oxygen than simple amides owing to the combined pi-donation from the two amino groups. One consequence is that the inventory of urea complexes is large, including many homoleptic derivatives. Urea forms a broader range of complexes, reflected by the existence of [M(urea)6](ClO4)3 (M = Ti, Mn). As for other complexes of carboxamide ligands, the MOC(NH2)2 core of urea is planar with a bent M-O-C angle. Biuret (H2NC(O)N(H)C(O)NH2) is a derivative of urea but with two amido groups. Biuret forms a variety of metal complexes, e.g. [Cu(H2NC(O)NHC(O)NH2)2]2+. In addition to the parent urea and biuret, many derivatives are known where N-H is replaced by alkyl or aryl.
== Early life and education == Oscar Tiegs' father, Prussian born Otto Theodor Carl Tiegs, and mother, Helene Caroline Ottilie, née Meyer, from Hanover, migrated to Australia from Germany. The Royal Society states that Otto Tiegs had careers in both pharmacy and engineering, and had a high regard for learning, while others state that he was a merchant. In particular, in 1920 under oath, Otto Tiegs described himself as a merchant. Oscar Tiegs was born at Kangaroo Point, a suburb of Brisbane. He had four younger sisters, two of whom died as infants. As a child, he was fascinated by insects and put together a collection of about one thousand named beetles, which was eventually taken in by the Queensland Museum. He described himself as a timid but industrious boy with an absorbing interest in insects, and acknowledged the support of the Queensland Government entomologist, Henry Tyson. He attended Brisbane State School until the age of 14, and Brisbane Grammar School from 1911 to 1915. He was awarded a scholarship to attend university.
joint pain – the most common symptom, occurring in up to 86% of patients. The pain is often an aching or arthritis-like pain in the elbows, wrists, hands, and knees, in a symmetrical pattern. dry eyes dry mouth hair loss joint inflammation mouth ulcers Raynaud's phenomenon sun-sensitive rash Clinical presentation in some people diagnosed with UCTD may show :
==== Somatostatin analogues ==== The primary medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). Somatostatin analogues are also sometimes used to shrink large tumors before surgery. Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one-third of people. In addition, approximately 25 percent of people with acromegaly develop gallstones, which are usually asymptomatic. In some cases, octreotide treatment can cause diabetes because somatostatin and its analogues can inhibit the release of insulin. With an aggressive adenoma that is not able to be operated on, there may be a resistance to octreotide in which case a second-generation SSA, pasireotide, may be used for tumor control. However, insulin and glucose levels should be carefully monitored as pasireotide has been associated with hyperglycemia by reducing insulin secretion.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.